Developing small molecules to treat a broad band of photoreceptor mutations
Mireca is a pre-clinical stage ophthalmology start-up company seated in Tübingen (Germany) aiming to bring its targeted, small molecule drug candidate to patients suffering from inherited retinal degeneration like Retinitis Pigmentosa, Leber’s congenital amaurosis, and Stargardt’s disease covering a broad range of mutations.
The company creates value through leveraging the combination of orphan size drug development, orphan market protection and a large combined market size protected by its proprietary intellectual property.
➤ PNAS Publication
Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration